

10/19/2016; Page 1

Suggested Formula	Urea 10% Topical Ointment (Suspension, 15 g)	FIN	F 006 654
----------------------	--	-----	-----------

## SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Urea, USP	1.500	g				
Glycerin, USP	1.5	mL				
Medisca AlpaWash <sup>TM</sup>	11.61	g				

## SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

*Hygroscopic* (protect from moisture whenever possible):

*Heat Sensitive* (protect from heat whenever possible):

Suggested Preparatory Guidelines

ion Sterile Preparation
To account for processing error considerations during preparation, it is suggested to
measure an additional 15 to 20% of the required quantities of ingredients.
T I I I I I I I I I I I I I I I I I I I
Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks
should always be worn.
This procedure requires the use of very small quantities of ingredients. All calculations
and preparation techniques must be verified before dispensing the final product.

Urea, Glycerin

Urea



10/19/2016; Page 2

Suggested Formula	Urea 10% Topical Ointment (Suspension, 15 g)	FIN	F 006 654	1
----------------------	--	-----	-----------	---

# SUGGESTED PREPARATION (for 15 g)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor <sup>(*)</sup> :	Processing Error	Qty. to measure
Urea, USP §	1.500	g			
Glycerin, USP §	1.5	mL			
Medisca AlpaWash <sup>TM</sup>	11.61	g	R		

§ Weigh / measure just prior to use.

\* Takes into account increased batch size conversions and density conversions, if required.

	Preparatory Instruction							
1.	Powder-liquid preparation:							
	A. Triturate the Urea to form a fine, homogeneous powder.							
	B. Levigate the fine homogeneous powder (Step 1A) with the Glycerin.							
	End result: Homogeneous paste-like dispersion.							
2.	Powder-liquid to medium integration:							
	A. Incrementally add the homogeneous paste-like dispersion (Step 1B) to the AlpaWash <sup>TM</sup> .							
	Specifications: Continuously mix, using high-shear mixing techniques.							
	End result: Homogeneous ointment-like dispersion.							
	B If the final result is gritty, pass it through the ointment mill until it becomes smooth and uniform.							
3.	Product transfer:							
	Transfer the final product into the specified dispensing container (see "Packaging Requirements").							



10/19/2016; Page 3

Suggested Formula	Urea 10% Topical Ointment (Suspension, 15 g)	FIN	F 006 654
----------------------	--	-----	-----------

## SUGGESTED PRESENTATION

	<b>SESTED FRE</b>					
-	Estimated Beyond-Use Date		6 months, as per USP*.	Packaging Requirements		<ul> <li>Tightly closed container.</li> <li>To be administered with a metered-dose measuring device.</li> </ul>
		1	Use as directed. Do not exceed dose.	1 prescribed	5	Keep in a dry place.
		2	Keep out of reach of children.		6	Cap tightly after use.
	Auxiliary Labels	3	Consult your health care practitioner if any		7	Keep at room temperature (20°C – 23°C).
		4	For external use only.			
	Pharmacist InstructionsNote: This non-sterile formulation, as per USP <3>, should not be applied to an open wound or burned area. If this formulation will be applied to an open wound or burned area, it must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within USP <797>. Also, in consideration of the overall formulation make-up and following the manufacturer's specifications, the suggested method of end-stage sterilization is gamma irradiation. The resulting BUD will be 30 days, as per USP <797>, based on a successful sterility test result.Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.					
	Patient	Co	ntact your pharmacist in the event	of adverse re	actior	15.
	Instructions	<b>IMPORTANT:</b> The quantity of API administered is directly dependent on the quantity of product applied.				

\* The BUD is not later than the time remaining until the earliest expiration date of any API or 6 months, whichever is earlier.



10/19/2016; Page 4

	Suggeste Formu		FIN	F 006 654							
REF	REFERENCES										
		Ointments, Creams, and Pastes. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Fourth Edition</i> . American Pharmaceutical Association; 2012: 265.									
	2. Uri	sec 40. In: Canadian Pharmacists Association. Compendium of Pharmacists and Specialtie	es, 201	5: 3156.							
		cerin. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients</i> , 7 <sup>th</sup> Edition. American Pharm 2: 324.	naceut	ical Association;							
4		Urea. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36<sup>th</sup> Edition.</i> London, England: The Pharmaceutical Press; 2009: 1620.									
-		Urea (Monograph). In: O'Neil MJ. The Merck Index 15th Edition. Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #10 052.         Urea. In: Trissel LA. Trissel's Stability of Compounded Formulations, 5th Edition. American Pharmaceutical Association; 2012: 493.         Urea (Monograph). United States Pharmacopeia XXXVIII / National Formulary 33. Rockville, MD. US Pharmacopeial Convention, Inc. 2015: 5720.									
•											
,											
1		USP <795>. United States Pharmacopeia XXXVIII / National Formulary 33. Rockville, MD. US Pharmacopeial Convention, Inc. 2015: 559.									

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.